Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients

Edmund Chiong; Ziteng Wang; Eleanor Jing Yi Cheong; Yi Chen Yao; Sin Mun Tham; Revathi Periaswami; Poh Choo Toh; Ziting Wang; Qing Hui Wu; Woon Chau Tsang; Arshvin Kesavan; Alvin Seng Cheong Wong; Patrick Thomas Wong; Felicia Lim; Shuaibing Liu; Eric Chun Yong Chan

doi:10.1002/cac2.70035

Cancer Communications ›› 2025, Vol. 45 ›› Issue (8) : 971 -975. DOI: 10.1002/cac2.70035

LETTER TO THE JOURNAL

Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients

Author information +

History +

PDF

Cite this article

Download citation ▾

Edmund Chiong, Ziteng Wang, Eleanor Jing Yi Cheong, Yi Chen Yao, Sin Mun Tham, Revathi Periaswami, Poh Choo Toh, Ziting Wang, Qing Hui Wu, Woon Chau Tsang, Arshvin Kesavan, Alvin Seng Cheong Wong, Patrick Thomas Wong, Felicia Lim, Shuaibing Liu, Eric Chun Yong Chan. Evaluation of exposure-response-safety relationship of model-informed low-dose 500 mg abiraterone acetate in prostate cancer patients. Cancer Communications, 2025, 45(8): 971-975 DOI:10.1002/cac2.70035

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26(28): 4563-71.

[2]	Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010; 28(9): 1481-8.

[3]	Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, et al. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020; 374(3): 438-51.

[4]	Cheong EJY, Chin SY, Ng ZW, Yap TJ, Cheong EZB, Wang Z, et al. Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement. Clin Pharmacokinet. 2023; 62(9): 1243-61.

[5]	Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018; 36(14): 1389-95.

[6]	Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, et al. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014; 17(2): 192-8.

[7]	Scher HI, Kelly WM, Zhang ZF, Ouyang P, Sun M, Schwartz M, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999; 91(3): 244-51.

[8]	Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, et al. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017; 72(1): 34-42.

[9]	Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, et al. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021; 27(21): 6001-11.

[10]	Rouleau M, Neveu B, Caron P, Morin F, Toren P, Lacombe L, et al. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level. J Urol. 2022; 208(6): 1214-25.